RedHill Biopharma (RDHL) Return on Sales (2016 - 2023)
Historic Return on Sales for RedHill Biopharma (RDHL) over the last 13 years, with Q4 2024 value amounting to 32.81%.
- RedHill Biopharma's Return on Sales rose 338200.0% to 32.81% in Q4 2024 from the same period last year, while for Dec 2024 it was 32.81%, marking a year-over-year increase of 338200.0%. This contributed to the annual value of 1.82% for FY2024, which is 54800.0% down from last year.
- As of Q4 2024, RedHill Biopharma's Return on Sales stood at 32.81%, which was up 338200.0% from 9.45% recorded in Q2 2024.
- RedHill Biopharma's Return on Sales' 5-year high stood at 32.81% during Q2 2023, with a 5-year trough of 6.58% in Q4 2021.
- Moreover, its 5-year median value for Return on Sales was 0.62% (2021), whereas its average is 4.67%.
- Data for RedHill Biopharma's Return on Sales shows a peak YoY increase of 338200bps (in 2024) and a maximum YoY decrease of -233500bps (in 2024) over the last 5 years.
- Over the past 5 years, RedHill Biopharma's Return on Sales (Quarter) stood at 0.7% in 2020, then plummeted by -1036bps to 6.58% in 2021, then increased by 17bps to 5.43% in 2022, then skyrocketed by 81bps to 1.02% in 2023, then soared by 3323bps to 32.81% in 2024.
- Its Return on Sales was 32.81% in Q4 2024, compared to 9.45% in Q2 2024 and 1.02% in Q4 2023.